BioSpace News Archive

MIRA Pharmaceuticals, Inc. announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder (PTSD) and other leading mental health disorders and neuropathic pain indications.

Xcell Biosciences Inc. and AmplifyBio today announced the launch of a partnership designed to streamline and improve the manufacturing process for engineered T-cell receptor (TCR) therapies targeting solid tumors.

Avenacy today announced it has launched Isoproterenol Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for ISUPREL ® as approved by the U.S. Food and Drug Administration.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation.

Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces the results of a groundbreaking independent study led by Mayo Clinic and presented at Digestive Disease Week 2024.